FDA warns of unapproved GLP-1 drugs as Hims shares fall 3.85%
AI Summary- FDA warned patients and providers about risks linked to unapproved and compounded GLP-1 medications.
- 990 adverse-event reports involved compounded semaglutide by May 31, 2026.
- Regulators targeted distributors, outsourcing facilities and telehealth vendors over unauthorized drugs.